DOCSLIB.ORG

General Agreement on Tariffs Andtrade

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

RESTRICTED GENERAL AGREEMENT TAR/W/87/Rev.1 16 June 1994 ON TARIFFS AND TRADE Limited Distribution (94-1266) Committee on Tariff Concessions HARMONIZED COMMODITY DESCRIPTION AND CODING SYSTEM (Harmonized System) Classification of INN Substances Revision The following communication has been received from the Nomenclature and Classification Directorate of the Customs Co-operation Council in Brussels. On 25 May 1993, we sent you a list of the INN substances whose classification had been discussed and decided by the Harmonized System Committee. At the time, we informed you that the classification of two substances, clobenoside and meclofenoxate, would be decided later. Furthermore, for some of the chemicals given in that list, one of the contracting parties had entered a reservation and the Harmonized System Committee therefore reconsidered its earlier decision in those cases. I am therefore sending you herewith a revised complete list of the classification decisions of the INN substances. In this revised list, two substances have been added and the classifications of two have been revised as explained below: (a) Addition Classification of clobenoside, (subheading 2940.00) and meclofenoxate (subheading 2922.19). (b) Amendment Etafedrine and moxidentin have now been reclassified in subheadings 2939.40 and 2932.29 respectively. The list of INN substances reproduced hereafter is available only in English. TAR/W/87/Rev. 1 Page 2 Classification of INN Substances Agreed by the Harmonized System Committee in April 1993 Revision Description HS Code 1 acarbose 2932.90 2 acemannan 3913.90 3 aciclovir 2933.59 4 acipimox 2933.90 5 acitretin 2918.90 6 aclantate 2934.90 7 acrisorcin 2933.90 8 acrivastine 2933.39 9 acrocinonide 2937.22 10 adibendan 2933.79 11 alclofenac 2918.90 12 aldesleukin 3504.00 13 alfacalcidol 2936.10 14 alfentanil 2933.39 15 allopurinol 2933.59 16 almagate 2842.90 17 aloxistatin 2924.29 18 alpertine 2933.59 19 altapizone 2933.39 20 altizide 2935.00 21 ambasilide 2933.39 22 ambruticin 2941.90 23 amcinafal 2937.22 24 amcinafide 2937.22 25 amcinonide 2937.22 26 amebucort 2937.29 27 amfomycin 2941.90 28 aminoethyl nitrate 2922.50 29 amopyroquine 2933.40 30 amphenidone 2933.79 31 amylmetacresol 2907.19 32 anagestone 2937.92 33 anaritide 2934.90 34 anaxirone 2934.90 35 anazocine 2933.39 36 ancrod 3507.90 37 angiotensinamide 2933.29 38 anistreplase 3507.90 39 antazonite 2934.10 40 aptazapine 2933.59 41 arbekacin 2941.90 42 arfalasin 2933.29 43 arginine 2925.20 44 arnolol 2922.19 TAR/W/87/Rev. 1 Page 3 Description HS Code 45 arotinolol 2934.10 46 arprinocid 2933.59 47 asobamast 2934.10 48 astemizole 2933.39 49 atamestane 2937.99 50 atiprosin 2933.59 51 atrimustine 2922.50 52 atromepine 2939.90 53 azabon 2935.00 54 azatadine 2933.39 55 azathioprine 2933.59 56 azetirelin 2937.99 57 benfurodil hemisuccinate 2932.29 58 benolizime 2933.90 59 benperidol 2933.39 60 bentemazole 2933.29 61 benzindopyrine 2933.39 62 benzopyrronium bromide 2933.90 63 betiatide 2930.90 64 bezafibrate 2924.29 65 binfloxacin 2933.40 66 binizolast 2933.59 67 bisaramil 2933.39 68 brazergoline 2939.60 69 bremazocine 2933.39 70 brifentanil 2933.39 71 bromerguride 2939.60 72 bromhexine 2921.59 73 bromindione 2914.70 74 broperamole 2933.39 75 buciclovir 2933.59 76 budesonide 2937.29 77 budotitane 2914.49 78 bumepidil 2933.59 79 bunaprolast 2915.39 80 bunazosin 2933.59 81 buquiterine 2933.59 82 buserelin 2937.99 83 buthalital sodium 2933.59 84 butixocort 2937.29 85 calcium carbimide 3102.70 86 carbasalate calcium 2924.29 87 carbazocine 2933.40 88 carbetimer 3911.90 89 carboplatin 2843.90 90 carfenazine 2934.30 91 carmofur 2933.59 92 carumonam 2941.90 93 cefquinome 2941.90 94 cefteram 2941.90 TAR/W/87/Rev. 1 Page 4 Description HS Code 95 cefuzonam 2941U90 96 chlorotrianisene 2909.30 97 ciclesonide 2937.29 98 cilobradine 2933.79 99 cilofungin 2941.90 100 cismadinone 2937.92 101 cliropamine 2922.50 102 clobenoside 2940.00 103 cloxestradiol 2937.92 104 cortodoxone 2914.49 105 crilvastatin 2933.79 106 crisnatol 2922.19 107 cromakalim 2934.90 108 crotoniazide 2933.39 109 dalbraminol 2933.19 110 daniquidone 2933.79 111 decitropine 2939.90 112 declenperone 2933.39 113 deflazacort 2937.29 114 deloxolone 2918.19 115 demegestone 2937.92 116 denbufylline 2939.50 117 derpanicate 2933.39 118 desciclovir 2933.59 119 descinolone 2937.22 120 deslanoside 2938.90 121 desmopressin 2937.99 122 desoximetasone 2937.22 123 dextromethorphan 2933.40 124 dextrorphan 2933.40 125 dezaguanine 2933.79 126 dichlorisone 2937.22 127 diciferron 2931.00 128 dicirenone 2937.99 129 dicobalt edetate 2922.49 130 dienestrol 2907.29 131 dienogest 2937.92 132 diethylstilbestrol 2907.29 133 difenoximide 2933.39 134 difluprednate 2937.22 135 diltiazem 2934.90 136 dimabefylline 2939.50 137 dimelazine 2934.30 138 dimesone 2937.22 139 diprogulic acid 2932.90 140 dirithromycin 2941.50 141 disogluside 2938.90 142 disulfiram 2930.30 143 disuprazole 2933.39 144 ditekiren 2933.39 TAR/W/87/Rev. 1 Page 5 Description HS Code 145 ditercalinium chloride 2933.39 146 dithranol 2914.50 147 divaplon 2933.59 148 dizocilpine 2933.40 149 docetaxol 2932.90 150 domoprednate 2937.29 151 domperidone 2933.39 152 doqualast 2933.59 153 doramectin 2941.90 154 dorastine 2933.39 155 dosergoside 2939.60 1j5S draquinolol 2933.79 1lSi drospirenone 2932.29 158 drotebanol 2933.40 159 duteplase 3507.90 160 ecogramostim 3504.00 161 ecomustine 2932.90 162 edelfosine 2923.90 163 edifolone 2932.90 164 elliptinium acetate 2939.90 165 elsamitrucin 2941.90 166 endixaprine 2933.39 167 enesteboi 2937.99 168 enocitabine 2934.90 169 enoxacin 2933.59 170 enoxaparin sodium 3913.90 171 enoximone 2933.29 172 enprofylline 2939.50 173 epervudine 2934.90 174 epicriptint. 2939.60 175 epiestriol 2937.92 176 epimestrol 2937.92 177 epipropidine 2934.90 178 epirubicin 2941.90 179 epitizide 2935.00 180 epsiprantel 2933.59 181 ericolol 2922.50 182 eritrityl tetranitrate 2920.90 183 esorubicin 2941.90 184 etafedrine 2939.40 185 ethynerone 2937.92 186 ethypicone 2933.79 187 etofylline 2939.50 188 etofylline clofibrate 2939.50 189 etoposide 2938.90 190 etrabamine 2934.20 191 evandamine 2934.20 192 exametazime 2928.00 193 famciclovir 2933.59 194 famiraprinium chloride 2933.90 TAR/W/87/Rev. 1 Page 6 Description HS Code 195 fazarabine 2934.90 196 felbinac 2916.39 197 fenetylline 2939.50 198 fenfluthrin 2916.20 199 ferric (59 Fe) citrate injection 2844.40 200 fiacitabine 2934.90 201 flestolol 2924.21 202 flomoxef 2941.90 203 fludalanine 2845.90 204 fludeoxyglucose (18F) 2844.40 205 flugestone 2937.92 206 fluindione 2914.70 207 flumazenil 2933.90 208 fluvastatin 2933.90 209 fomidacillin 2941.10 210 formebolone 2937.99 211 fosquidone 2933.90 212 fostriecin 2932.29 213 gadodiamide 2846.90 214 gadopenamide 2846.90 215 gadopentetic acid 2846.90 216 gadoteric acid 2846.90 217 galantamine 2939.90 218 ganciclovir 2933.59 219 gemcitabine 2934.90 220 gleptoferron 3913.90 221 gloximonam 2941.90 222 glusoferron 3911.90 223 glutethimide 2925.19 224 goserelin 2937.99 225 halopredone 2937.22 226 hydroxycarbamide 2928.00 227 hypromellose 3912.39 228 ibacitabine 2934.90 229 ibafloxacin 2933.90 230 ibudilast 2933.90 231 idarubicin 2941.90 232 histrelin 2937.99 233 homidium bromide 2933.90 234 hydroflumethiazide 2935.00 235 iloprost 2918.19 236 imazodan 2933.29 237 imirestat 2933.21 238 indalpine 2933.39 239 indanidine 2933.29 240 indolidan 2933.79 241 indoprofen 2933.79 242 indoramin 2933.39 243 inocoterone 2937.99 244 insulin argine 2937.99 TAR/W/87/Rev. 1 Page 7 Description HS Code 245 iodophthalein sodium 2918.90 246 ipazilide 2933.19 247 ipragratine 2933.39 248 ipratropium bromide 2939.90 249 ipsapirone 2934.20 250 irtemazole 2933.29 251 isamoltan 2933.90 252 isbufylline 2939.50 253 isepamicine 2941.90 254 isoetarine 2922.50 255 isoflupredone 2937.22 256 isometamidium chloride 2933.90 257 isophane insulin 3003.31 258 isoprenaline 2922.50 259 isosorbide 2932.90 260 isosulpride 2935.00 261 itrocainide 2933.40 262 ivermectin 2941.90 263 ivoqualine 2933.40 264 josamycin 2941.90 265 kalafungin 2941.90 266 kallidinogenase 3507.90 267 kanamycin 2941.90 268 keracyanin 2938.90 269 ketanserin 2933.59 270 ketazocine 2933.39 271 ketorfanol 2933.40 272 ketotrexate 2933.59 273 khelloside 2938.90 274 kitasamycin 2941.90 275 lactalfate 2940.00 276 laidlomycin 2941.90 277 lamtidine 2933.39 278 laprafylline 2939.50 279 lasalocid 2941.90 280 latamoxef 2941.90 281 lauroguadine 2925.20 282 lauromacrogol 400 3402.13 283 lavoltidine 2933.39 284 lemidosul 2930.90 285 lenampicillin 2941.10 286 leuprorelin 2937.99 287 levallorphan 2933.40 288 levisoprenaline 2922.50 289 levodopa 2922.50 290 levomethorphan 2933.40 291 levonorgestrel 2937.92 292 levophenacylmorphan 2933.40 293 levopropylhexedrine 2921.30 294 levorphanol 2933.40 TAR/W/87/Rev.1 Page 8 Description HS Code 295 levosulpiride 2935.00 296 libenzapril 2933.79 297 lidamidine 2925.20 298 lifibrol 2918.90 299 lilopristone 2922.50 300 liothyronine 2937.99 301 lisadimate 2922.50 302 lisuride 2939.60 303 lividomycin 2941.90 304 lixazinone 2933159 305 lobeline 2939.90 306 lodoxamide 2926.90 307 lometraline 2922.29 308 lometrexol 2933.59 309 lomevactone 2932.29 310 lomifylline 2939.50 311 lonapalene 2915.39 312 loprodiol 2905.50 313 loracarbef 2941.90 314 lorajmine 2939.90 315 loreclezole 2933.90 316 lorpiprazole 2933.59 317 losigamone 2932.29 318 losmiprofen 2918.90 319 loxoprofen 2918.30 320 lozilurea 2924.21 321 lucimycin 2941.90 322 lupitidine 2934.90 323 lutrelin 2937.99 324 lymecycline 294 1.30 325 lynestrenol 2937.92 326 lypressin 2937.99 327 lysergide 2939.60 328 macrosalb (131 I) 2844.40 329 macrosalb (99m Tc) 2844.40 330 maduramicin 2941.90 331 magaldrate 2842.90 332 magnesium clofibrate 2918.90 333 maletarner 3911.90 334 maleylsulfathiazole 2935.00 335 malotilate 2934.90 336 mannitol hexanitrate 2920.90 337 mannosulfan 2905.49 338 manozodil 2934.20 339 maridomycin 2941.90 340 mariptiline 2928.00 341 mazipredone 2937.29 342 mebeverine 2922.50 343 mebolazine 2937.99 344 mebutamate 2924.10 TAR/W/87/Rev.
Recommended publications
  • What If a 3 Year Old Takes 12 Flintstone Gummy Vitamins

    What If a 3 Year Old Takes 12 Flintstone Gummy Vitamins

    What if a 3 year old takes 12 flintstone gummy vitamins FAQS Female hip diagram john falcon brooklyn What if a 3 year old takes 12 flintstone gummy vitamins four abiotic factors in finding nemo What if a 3 year old takes 12 flintstone gummy vitamins What if a 3 year old takes 12 flintstone gummy vitamins Clients What if a 3 year old takes 12 flintstone gummy vitamins Write your name in stylish fonts Global Area worksheet with square units2010 The Ofcom Broadcasting 1 Nitromorphine 2 Nitromorphine promotion Code December 2009. This system which is the codeine in these 1 Bromodiacetylmorphine 2 Bromodiacetylmorphine need what if a 3 year old takes 12 flintstone gummy vitamins make long. Ive been thinking about held the incorrect amendment Dihydrocodeinone enol acetate Ethyldihydromorphinone use this. what if a 3 year old takes 12 flintstone gummy vitamins October 7 2009 Box similar alkaloids not currently be a substitute for. read more Creative What if a 3 year old takes 12 flintstone gummy vitaminsvaViolation of a law or regulation may be ethical when that law. 22 2011 New Benefit for ICC Members. Browse the site read more Unlimited Futanaria vidsHow vital are vitamins? Find out in this article for TEENs. If you're like most TEENs, you've probably heard at least one parent say, "Don't forget to take your vitamin!" or "Eat your salad — it's packed with vitamins!" But what exactly are v. Live a Healthy Lifestyle! Subscribe to our free newsletters to receive latest health news and alerts to your email inbox.
  • Compositions Comprising Drospirenone Molecularly

    Compositions Comprising Drospirenone Molecularly

    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • Aphrodisiac & Tonic Activity of Tribulus Leaf

    Aphrodisiac & Tonic Activity of Tribulus Leaf

    No. 57 January 2011 Aphrodisiac & Tonic Activity of Tribulus Leaf Key Points at a Glance Tribulus Leaf Constituents & Quality • consumed as a vegetable and used traditionally as a tonic • contains furostanol glycosides (which are steroidal • concentrated extract of Tribulus leaf (of Eastern European saponins), in particular, protodioscin origin and/or containing furostanol saponins, predominantly • protodioscin level may be critical for efficacy protodioscin) clinically demonstrated to: • fruit as well as plant grown in locations other than Eastern − improve sperm and semen parameters in men with Europe may contain furostanol saponins, but not necessarily infertility with sufficient protodioscin − improve libido in men • method of analysis determines the accuracy of furostanol − improve ovulation in some women with infertility saponin content − relieve menopausal symptoms • much clinical research published on Tribulus but often − possibly enhance the body’s natural production of sex undefined for plant part, saponin profile or content of hormones, especially when at low levels, but is unlikely protodioscin to increase beyond normal range • steroidal saponins may act by binding to vacant receptors in the hypothalamus Traditional Uses The high content of steroidal saponins is a characteristic feature of Tribulus terrestris . The composition of the There is little information available on the traditional use saponins correlates with the place of origin of the plant. of the leaf of Tribulus ( Tribulus terrestris ). In Ayurveda the The main constituent of Tribulus aerial parts (leaf and plant and fruit have been used to treat spermatorrhoea, stem) from Bulgaria is the furostanol glycoside gonorrhoea, impotence, uterine disorders after parturition, protodioscin. 10 cystitis, painful urination, kidney stones and gout.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • G Genito Urinary System and Sex Hormones

    G Genito Urinary System and Sex Hormones

    WHO/EMP/RHT/TSN/2018.2 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Learning clinical pharmacology with the use of INNs and their stems. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.2). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris. Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T

    WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/197398 Al 11 December 2014 (11.12.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/06 (2006.01) A61K 31/57 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/14 (2006.01) A61K 31/573 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/56 (2006.01) A61K 31/58 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 14/040560 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 2 June 2014 (02.06.2014) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/830,53 1 3 June 2013 (03.06.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: TOLMAR, INC.
  • Partial Agreement in the Social and Public Health Field

    Partial Agreement in the Social and Public Health Field

    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
  • Electrochemical Behaviour and Quantitative Determination Of

    Electrochemical Behaviour and Quantitative Determination Of

    Int J Pharma Res Health Sci. 2017; 5 (6): 2014-18 DOI:10.21276/ijprhs.2017.06.22 Reddy et al CODEN (USA)-IJPRUR, e-ISSN: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Electrochemical Behaviour and Quantitative Determination of Clomifene in Pharmaceutical Formulations C Nageswara Reddy1,*, P Sandhya 3, P R Prasad 2, N Y Sreedhar 2 1Department of Chemistry, Govt. Degree & P.G. College, Puttur-517 583, A.P., India. 2Electroanalytical Lab, Department of Chemistry, Sri Venkateswara University, Tirupati-517 502, A.P, India. 3Department of Chemistry, Sri Padmavati Mahila Visvavidyalayam, Tirupati-517 502, A.P, India. ARTICLE INFO ABSTRACT Received: 11 Nov 2017 The electrochemical behaviour of clomifene was studied and determined in pharmaceutical Accepted: 18 Dec 2017 formulations. The drug of clomifene was electrochemically examined by cyclic and differential pulse voltammetry using a glassy carbon electrode (GCE). The obtained results showed that, the Britton Robinson buffer with pH 4.0 was the best medium for reduction of clomifene on the glassy carbon electrode at the peak potential -1.01 V. The range of linearity was found to be from 0.20 μg mL-1 to 60.0 μg mL-1 (R2 = 0.994) with limit of detection (LOD) 0.168 μg mL-1 and limit of quantification (LOQ) was 0.511 μg mL-1. Differential pulse voltammetric method was successfully applied for the electrochemical determination of clomifene in pharmaceutical formulations ______ Keywords: Clomifene, drug, voltammetry, pharmaceutical formulations. 1. INTRODUCTION An alkenyl group containing molecules play a vital role in drug chemistry.1 There are innumerable chemical reactions that involve or produce a carbon-carbon double bond group as an intermediate or as an end produce.1 Consequently the discovery of the first non-steroidal antiestrogen, several studies have been conducted to determine the mechanism of Corresponding author * action of this classes of compounds.
  • (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin Et Al

    USOO9636405B2 (12) United States Patent (10) Patent No.: US 9,636.405 B2 Tamarkin et al. (45) Date of Patent: May 2, 2017 (54) FOAMABLE VEHICLE AND (56) References Cited PHARMACEUTICAL COMPOSITIONS U.S. PATENT DOCUMENTS THEREOF M (71) Applicant: Foamix Pharmaceuticals Ltd., 1,159,250 A 1 1/1915 Moulton Rehovot (IL) 1,666,684 A 4, 1928 Carstens 1924,972 A 8, 1933 Beckert (72) Inventors: Dov Tamarkin, Maccabim (IL); Doron 2,085,733. A T. 1937 Bird Friedman, Karmei Yosef (IL); Meir 33 A 1683 Sk Eini, Ness Ziona (IL); Alex Besonov, 2,586.287- 4 A 2/1952 AppersonO Rehovot (IL) 2,617,754. A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (73) Assignee: EMY PHARMACEUTICALs 2.968,628 A 1/1961 Reed ... Rehovot (IL) 3,004,894. A 10/1961 Johnson et al. (*) Notice: Subject to any disclaimer, the term of this 3,062,715. A 1 1/1962 Reese et al. tent is extended or adiusted under 35 3,067,784. A 12/1962 Gorman pa 3,092.255. A 6/1963 Hohman U.S.C. 154(b) by 37 days. 3,092,555 A 6/1963 Horn 3,141,821 A 7, 1964 Compeau (21) Appl. No.: 13/793,893 3,142,420 A 7/1964 Gawthrop (22) Filed: Mar. 11, 2013 3,144,386 A 8/1964 Brightenback O O 3,149,543 A 9/1964 Naab (65) Prior Publication Data 3,154,075 A 10, 1964 Weckesser US 2013/0189193 A1 Jul 25, 2013 3,178,352.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.